BARDA and Clarivate partner to accelerate development efforts in the identification of therapeutics that can treat chlorine or sulfur mustard injuries
We are excited to partner with the Biomedical Advanced Research and Development Authority (BARDA) to help in the identification of therapeutics that can be leveraged to treat chemical exposure. BARDA, which provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies, will leverage Clarivate Consulting Service’s computational approach to screen drug candidates most likely to be repurposed successfully for treating chemical exposures.
As a company at the forefront of target identification, indication prioritization, mechanism reconstruction and drug repurposing work in the pharmaceutical industry, Clarivate will identify drugs that are commonly available and can be used as medical countermeasures (MCMs) against chlorine and sulfur mustard induced injuries. The Clarivate suite of research intelligence solutions used in the project will include MetaBase, Cortellis Drug Discovery Intelligence, OFF-X, and real-world data featured within the Clarivate Research Intelligence Cloud.
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50121C00031.
To learn more about the collaboration, visit DRIVe’s ReDIRECT program here.